Statement of Changes in Beneficial Ownership (4)
June 02 2021 - 5:22PM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Blakeman Shaun M. |
2. Issuer Name and Ticker or Trading Symbol
CANTEL MEDICAL CORP
[
CMD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP - CFO |
|
(Last)
(First)
(Middle)
150 CLOVE ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/2/2021 |
|
(Street)
LITTLE FALLS, NJ 07424
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock, par value $.10 per share | 6/2/2021 | | D(1)(2) | | 13953 (1)(2) | D | $80.59 (1)(2) | 0 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). |
| (2) | Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Blakeman Shaun M.
150 CLOVE ROAD
LITTLE FALLS, NJ 07424 |
|
| SVP - CFO |
|
Signatures
|
| /s/ Shaun M. Blakeman | | 6/2/2021 |
| **Signature of Reporting Person | Date |
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Oct 2024 to Nov 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Nov 2023 to Nov 2024
